Lipocine Total Current Liabilities vs Retained Earnings Analysis
| LPCN Stock | USD 4.49 0.05 1.13% |
Lipocine financial indicator trend analysis is infinitely more than just investigating Lipocine recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lipocine is a good investment. Please check the relationship between Lipocine Total Current Liabilities and its Retained Earnings accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.
Total Current Liabilities vs Retained Earnings
Total Current Liabilities vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lipocine Total Current Liabilities account and Retained Earnings. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Lipocine's Total Current Liabilities and Retained Earnings is -0.7. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Lipocine, assuming nothing else is changed. The correlation between historical values of Lipocine's Total Current Liabilities and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Lipocine are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Total Current Liabilities i.e., Lipocine's Total Current Liabilities and Retained Earnings go up and down completely randomly.
Correlation Coefficient | -0.7 |
| Relationship Direction | Negative |
| Relationship Strength | Weak |
Total Current Liabilities
Total Current Liabilities is an item on Lipocine balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Lipocine are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from Lipocine's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lipocine current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.As of the 1st of October 2024, Selling General Administrative is likely to grow to about 5.8 M, while Tax Provision is likely to drop 411.40.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 16.6M | 11.8M | 14.9M | 9.3M | Cost Of Revenue | 7.7M | 8.6M | 28.7K | 27.2K |
Lipocine fundamental ratios Correlations
Click cells to compare fundamentals
Lipocine Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lipocine fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 19.7M | 25.4M | 52.5M | 37.5M | 23.0M | 29.7M | |
| Other Current Liab | 449.3K | 1.7M | 1M | 1.1M | 1.2M | 1.5M | |
| Total Current Liabilities | 5.0M | 6.6M | 5.6M | 1.7M | 2.6M | 3.4M | |
| Total Stockholder Equity | 6.3M | 15.3M | 45.6M | 35.6M | 20.4M | 24.6M | |
| Net Debt | (2.6M) | (13.6M) | (639.7K) | (3.1M) | (4.8M) | (5.0M) | |
| Retained Earnings | (151.1M) | (172.0M) | (172.7M) | (183.4M) | (199.8M) | (189.8M) | |
| Accounts Payable | 1.2M | 1.6M | 1.3M | 600.4K | 1.4M | 798.8K | |
| Cash | 9.7M | 19.2M | 3.0M | 3.1M | 4.8M | 9.2M | |
| Cash And Short Term Investments | 14.1M | 19.7M | 44.6M | 32.5M | 22.0M | 26.6M | |
| Common Stock Total Equity | 2.2K | 3.8K | 7.0K | 8.8K | 10.2K | 10.7K | |
| Common Stock Shares Outstanding | 1.5M | 3.3M | 5.2M | 5.3M | 5.3M | 5.5M | |
| Liabilities And Stockholders Equity | 19.7M | 25.4M | 52.5M | 37.5M | 23.0M | 29.7M | |
| Other Current Assets | 545.9K | 661.3K | 1.5M | 945.3K | 773.4K | 1.0M | |
| Other Stockholder Equity | 157.4M | 187.4M | 218.2M | 219.1M | 220.1M | 147.6M | |
| Total Liab | 13.4M | 10.0M | 6.9M | 1.9M | 2.6M | 5.1M | |
| Total Current Assets | 19.6M | 25.3M | 46.4M | 34.1M | 22.9M | 28.8M | |
| Common Stock | 3.8K | 7.0K | 8.8K | 8.9K | 8.9K | 9.3K | |
| Property Plant Equipment | 19.0K | 3.6K | 7.2K | 131.6K | 118.4K | 124.4K | |
| Net Tangible Assets | 6.3M | 15.3M | 45.6M | 35.6M | 41.0M | 27.0M | |
| Retained Earnings Total Equity | (138.1M) | (151.1M) | (172.0M) | (172.7M) | (155.4M) | (163.2M) | |
| Short Term Investments | 4.3M | 450.0K | 41.7M | 29.4M | 17.3M | 15.1M | |
| Capital Surpluse | 147.5M | 157.4M | 187.4M | 218.3M | 251.0M | 143.4M | |
| Property Plant And Equipment Net | 3.6K | 0.0 | 7.2K | 131.6K | 116.1K | 63.4K | |
| Non Current Assets Total | 27.3K | 23.8K | 6.1M | 3.4M | 139.8K | 132.9K | |
| Property Plant And Equipment Gross | 3.6K | 1.1M | 1.2M | 1.3M | 1.3M | 1.4M | |
| Net Receivables | 16.5K | 391.0 | 247.3K | 659.9K | 52.3K | 49.6K | |
| Net Invested Capital | 13.4M | 20.9M | 47.9M | 35.6M | 20.4M | 27.8M | |
| Net Working Capital | 14.7M | 18.7M | 40.8M | 32.5M | 20.2M | 25.5M | |
| Short Long Term Debt Total | 7.1M | 5.6M | 2.3M | 17.2K | 15.4K | 14.7K | |
| Capital Stock | 3.8K | 7.0K | 8.8K | 8.9K | 8.9K | 7.2K |
Pair Trading with Lipocine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipocine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipocine will appreciate offsetting losses from the drop in the long position's value.Moving together with Lipocine Stock
Moving against Lipocine Stock
| 0.95 | ABBV | AbbVie Inc | PairCorr |
| 0.89 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.88 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.81 | AQST | Aquestive Therapeutics Buyout Trend | PairCorr |
| 0.67 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Lipocine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipocine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipocine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipocine to buy it.
The correlation of Lipocine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipocine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipocine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipocine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Information and Resources on Investing in Lipocine Stock
When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.903 | Quarterly Revenue Growth 137.519 | Return On Assets (0.23) | Return On Equity (0.34) |
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.